Amphastar Pharmaceuticals (NASDAQ:AMPH) Trading 3.3% Higher – What’s Next?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) shares traded up 3.3% during mid-day trading on Monday . The stock traded as high as $32.16 and last traded at $32.33. 64,789 shares traded hands during trading, a decline of 88% from the average session volume of 521,971 shares. The stock had previously closed at $31.28.

Analysts Set New Price Targets

AMPH has been the topic of several recent analyst reports. Wells Fargo & Company started coverage on Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They set an “equal weight” rating and a $55.00 target price on the stock. Piper Sandler lowered shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $66.00 to $36.00 in a research note on Tuesday, February 4th. Finally, StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $50.33.

Amphastar Pharmaceuticals Price Performance

The company has a market cap of $1.50 billion, a price-to-earnings ratio of 10.40, a PEG ratio of 2.19 and a beta of 0.81. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The company’s 50 day moving average price is $35.27 and its 200-day moving average price is $42.83.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 7,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $44.42, for a total transaction of $310,940.00. Following the transaction, the executive vice president now directly owns 118,469 shares in the company, valued at approximately $5,262,392.98. The trade was a 5.58 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Richard K. Prins sold 10,000 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $43.77, for a total transaction of $437,700.00. Following the sale, the director now directly owns 30,471 shares in the company, valued at approximately $1,333,715.67. This trade represents a 24.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 27.10% of the company’s stock.

Institutional Trading of Amphastar Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. Pacer Advisors Inc. raised its position in Amphastar Pharmaceuticals by 51,977.4% during the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock valued at $50,139,000 after buying an additional 1,347,775 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Amphastar Pharmaceuticals by 9.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company’s stock valued at $44,503,000 after purchasing an additional 105,288 shares during the period. Boston Trust Walden Corp lifted its position in shares of Amphastar Pharmaceuticals by 81.4% in the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock worth $36,347,000 after purchasing an additional 439,281 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Amphastar Pharmaceuticals by 1.5% in the third quarter. Geode Capital Management LLC now owns 920,363 shares of the company’s stock worth $44,674,000 after purchasing an additional 14,015 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Amphastar Pharmaceuticals by 5.1% during the fourth quarter. Northern Trust Corp now owns 613,170 shares of the company’s stock worth $22,767,000 after purchasing an additional 29,808 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.